Rising prevalence of Plasmodium falciparum Artemisinin partial resistance mutations in Ethiopia.

IF 5.4 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Bokretsion G Brhane, Abebe A Fola, Helen Nigussie, Alec Leonetti, Moges Kassa, Henok Hailgiorgis, Yonas Wuletaw, Adugna Abera, Hussein Mohammed, Heven Sime, Abeba G/Tsadik, Gudissa Assefa, Hiwot Solomon, Geremew Tasew, Getachew Tollera, Mesay Hailu, Jonathan J Juliano, Ashenafi Assefa, Jonathan B Parr, Jeffrey A Bailey
{"title":"Rising prevalence of Plasmodium falciparum Artemisinin partial resistance mutations in Ethiopia.","authors":"Bokretsion G Brhane, Abebe A Fola, Helen Nigussie, Alec Leonetti, Moges Kassa, Henok Hailgiorgis, Yonas Wuletaw, Adugna Abera, Hussein Mohammed, Heven Sime, Abeba G/Tsadik, Gudissa Assefa, Hiwot Solomon, Geremew Tasew, Getachew Tollera, Mesay Hailu, Jonathan J Juliano, Ashenafi Assefa, Jonathan B Parr, Jeffrey A Bailey","doi":"10.1038/s43856-025-01008-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ethiopia aims to eliminate local malaria transmission by 2030, but rising malaria cases, due to different factors, present a challenge. Understanding the prevalence and distribution of artemisinin partial resistance (ART-R) and other markers related to partner drugs as well as parasite connectivity in Ethiopia can greatly inform malaria control.</p><p><strong>Methods: </strong>We analyzed 1199 clinical Plasmodium falciparum infections from 12 sentinel sites across five regions in Ethiopia, collected between 2019 and 2023. Using two molecular inversion probe (MIP) panels targeting key drug resistance genes and genome-wide SNPs, we assessed the prevalence of resistance-associated mutations, complexity of infection (COI), and parasite relatedness through identity-by-descent (IBD) and principal component analysis (PCA).</p><p><strong>Results: </strong>The most prevalent k13 R622I mutation appears in 15.7% of samples, with marked regional variation. Three validated ART-R mutations (P441L, P574L, A675V) are detected in Ethiopia for the first time, as far as we are aware, with A675V found exclusively in a Gambella clinic serving refugees from Sudan and South Sudan. Additionally, polymorphisms associated with resistance to partner drugs, including those in crt, mdr1, dhps, and dhfr genes, are nearly fixed. Most samples (87.2%) consist of monogenomic infections (COI = 1), and mutant parasites show high local genetic relatedness at the health facility level, suggesting clonal transmission. PCA reveals regional clustering, particularly in Gambella, highlighting the influence of local drug pressure, regional transmission dynamics, and importation as drivers of the observed drug resistance patterns.</p><p><strong>Conclusions: </strong>The increasing prevalence of k13 R622I and the emergence of additional ART-R mutations underscore the urgent need for enhanced ACT efficacy monitoring. Early detection of partner drug resistance and ACT failure will be essential to address malaria resurgence and support Ethiopia's elimination goals.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"297"},"PeriodicalIF":5.4000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274420/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communications medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s43856-025-01008-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ethiopia aims to eliminate local malaria transmission by 2030, but rising malaria cases, due to different factors, present a challenge. Understanding the prevalence and distribution of artemisinin partial resistance (ART-R) and other markers related to partner drugs as well as parasite connectivity in Ethiopia can greatly inform malaria control.

Methods: We analyzed 1199 clinical Plasmodium falciparum infections from 12 sentinel sites across five regions in Ethiopia, collected between 2019 and 2023. Using two molecular inversion probe (MIP) panels targeting key drug resistance genes and genome-wide SNPs, we assessed the prevalence of resistance-associated mutations, complexity of infection (COI), and parasite relatedness through identity-by-descent (IBD) and principal component analysis (PCA).

Results: The most prevalent k13 R622I mutation appears in 15.7% of samples, with marked regional variation. Three validated ART-R mutations (P441L, P574L, A675V) are detected in Ethiopia for the first time, as far as we are aware, with A675V found exclusively in a Gambella clinic serving refugees from Sudan and South Sudan. Additionally, polymorphisms associated with resistance to partner drugs, including those in crt, mdr1, dhps, and dhfr genes, are nearly fixed. Most samples (87.2%) consist of monogenomic infections (COI = 1), and mutant parasites show high local genetic relatedness at the health facility level, suggesting clonal transmission. PCA reveals regional clustering, particularly in Gambella, highlighting the influence of local drug pressure, regional transmission dynamics, and importation as drivers of the observed drug resistance patterns.

Conclusions: The increasing prevalence of k13 R622I and the emergence of additional ART-R mutations underscore the urgent need for enhanced ACT efficacy monitoring. Early detection of partner drug resistance and ACT failure will be essential to address malaria resurgence and support Ethiopia's elimination goals.

埃塞俄比亚恶性疟原虫青蒿素部分耐药突变流行率上升。
背景:埃塞俄比亚的目标是到2030年消除当地疟疾传播,但由于各种因素,疟疾病例不断上升,这是一个挑战。了解埃塞俄比亚青蒿素部分耐药(ART-R)和其他与伙伴药物相关的标志物以及寄生虫连通性的流行和分布,可为疟疾控制提供重要信息。方法:我们分析了2019年至2023年在埃塞俄比亚5个地区的12个哨点收集的1199例临床恶性疟原虫感染病例。研究人员利用针对关键耐药基因和全基因组snp的两个分子倒置探针(MIP)面板,通过血统鉴定(IBD)和主成分分析(PCA)评估了耐药相关突变的患病率、感染的复杂性(COI)以及寄生虫的相关性。结果:15.7%的样本中k13 R622I突变最为普遍,区域差异显著。据我们所知,在埃塞俄比亚首次检测到三种经过验证的ART-R突变(P441L, P574L, A675V),其中A675V仅在为苏丹和南苏丹难民服务的甘贝拉诊所中发现。此外,与伴体药物耐药相关的多态性,包括crt、mdr1、dhps和dhfr基因,几乎是固定的。大多数样本(87.2%)由单基因组感染组成(COI = 1),突变寄生虫在卫生机构水平上显示出高度的本地遗传相关性,表明克隆传播。PCA揭示了区域聚类,特别是在甘贝拉,突出了当地药物压力、区域传播动态和进口作为观察到的耐药模式驱动因素的影响。结论:k13 R622I患病率的增加和ART-R突变的出现强调了加强ACT疗效监测的迫切需要。早期发现伙伴的耐药性和以青蒿素为基础的联合疗法失败,对于应对疟疾死灰复燃和支持埃塞俄比亚实现消除疟疾的目标至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信